Spyre reports positive Phase 2 SKYLINE Part A induction data for UC drug SPY003, hits primary endpoint
SYRE•Phase 2 SKYLINE Part A induction results
Spyre Therapeutics reported positive 12-week induction results from Part A of its Phase 2 SKYLINE trial of SPY003 in ulcerative colitis.
- Findings showed meaningful improvement in disease activity, supporting SPY003’s potential as a competitive anti-IL-23 option.
- The safety profile was consistent with the IL-23 drug class, supporting continued development in combination regimens.
- Enrollment continues in SKYLINE Part B, which tests monotherapies and pairwise combinations; topline induction results are expected in 2027.
